{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:21Z","timestamp":1740106941569,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00277-023-05370-8","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T19:01:16Z","timestamp":1690052476000},"page":"3271-3273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alemtuzumab induced acquired hemophilia A in multiple sclerosis: a case report"],"prefix":"10.1007","volume":"102","author":[{"given":"Hassan","family":"Fawaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hassan","family":"Hodroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hawraa","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirine O.","family":"Trad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8515-2238","authenticated-orcid":false,"given":"Ali","family":"Taher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"5370_CR1","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.msard.2020.102181","volume":"44","author":"ER Comini-Frota","year":"2020","unstructured":"Comini-Frota ER et al (2020) Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: a report of two cases. Mult Scler Relat Disord 44:102181","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"5370_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","volume":"32","author":"S Faissner","year":"2018","unstructured":"Faissner S, Gold R (2018) Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs 32(3):269\u2013287","journal-title":"CNS Drugs"},{"issue":"5","key":"5370_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","volume":"109","author":"PW Collins","year":"2007","unstructured":"Collins PW et al (2007) Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation. Blood 109(5):1870\u20131877","journal-title":"Blood"},{"issue":"8","key":"5370_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D et al (2017) Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 74(8):961\u2013969","journal-title":"JAMA Neurol"},{"issue":"3","key":"5370_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","volume":"83","author":"GA Hill-Cawthorne","year":"2012","unstructured":"Hill-Cawthorne GA et al (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83(3):298\u2013304","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"5370_CR6","doi-asserted-by":"publisher","first-page":"e000095","DOI":"10.1136\/bmjno-2020-000095","volume":"3","author":"K Gounder","year":"2021","unstructured":"Gounder K, Batt T, Dreyer M (2021) Two case reports of acquired haemophilia A as complications of alemtuzumab treatment for multiple sclerosis. BMJ Neurol Open 3(1):e000095","journal-title":"BMJ Neurol Open"},{"key":"5370_CR7","doi-asserted-by":"publisher","unstructured":"Madeley J, Hodges G, Birchley A (2018) Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis. BMJ Case Rep\u00a02018:bcr2018226588. https:\/\/doi.org\/10.1136\/bcr-2018-226588","DOI":"10.1136\/bcr-2018-226588"},{"key":"5370_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.msard.2018.11.029","volume":"27","author":"M Pisa","year":"2019","unstructured":"Pisa M et al (2019) Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report. Mult Scler Relat Disord 27:403\u2013405","journal-title":"Mult Scler Relat Disord"},{"key":"5370_CR9","doi-asserted-by":"publisher","unstructured":"McCaughan G, Massey J, Sutton I, Curnow J (2017) Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis. BMJ Case Rep 2017:bcr2017223016. https:\/\/doi.org\/10.1136\/bcr-2017-223016","DOI":"10.1136\/bcr-2017-223016"},{"issue":"1","key":"5370_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjh.16644","volume":"190","author":"HS Brink","year":"2020","unstructured":"Brink HS, Moll W, Sandberg Y (2020) Acquired haemophilia A after alemtuzumab treatment of multiple sclerosis. Br J Haematol 190(1):13","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:14:51Z","timestamp":1697019291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5370"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05370-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}